Windlas Biotech Ltd (NSE: WINDLAS, BSE: 543329) is a Dehradun, Uttarakhand-based company in the Domestic contract manufacturers industry. With a market capitalisation of ₹1,801 Cr, it ranks #1,253 by market cap among the 6,189 Indian listed companies on FinBizNet, and #3 of 4 in Domestic contract manufacturers. At ₹872.70 (as of 26 Oct 2026), the share price is 26.2% below its 52-week high of ₹1,181.90 and 25.1% above its 52-week low of ₹697.40. The share price is down 5.3% over one year and up 1.7% over three months.
| Current Price | ₹872.70 |
|---|---|
| Market Cap | ₹1,801 Cr |
| NSE Symbol | WINDLAS |
| BSE Code | 543329 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Domestic contract manufacturers |
| P/E Ratio | 28 |
| Return on Equity | 12.23% |
| Return on Assets | 5.55% |
| 52-Week Range | ₹697.40 – ₹1,181.90 |
| 1-Year Price Change | -5.3% |
| 3-Month Price Change | +1.7% |
| Beta (1Y) | 0.37 |
| Dividend Yield | 0.72% |
| Headquarters | Dehradun, Uttarakhand |
| Website | windlas.com |
| Revenue | ₹248 Cr |
|---|---|
| Net Profit | ₹18 Cr |
| Net Margin | 7.1% |
| EPS (Basic) | ₹8.46 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradu
1. Pharmaceutical-This segment offers pharmaceutical development and manufacturing services, and products.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | ₹10,243 Cr | 40.1 | 8.02% | ₹1,167 Cr | +44.4% |
| INNOVA CAPTAB LIMITED | ₹5,650 Cr | 40.1 | 14.03% | ₹471 Cr | +19.4% |
| Windlas Biotech Ltd | ₹1,801 Cr | 28 | 12.23% | ₹248 Cr | -5.3% |
| Influx Healthtech Limited | ₹595 Cr | 27.5 | — | — | — |
Listed by market capitalisation. Ratios are shown for context only.
Windlas Biotech Ltd is trading at ₹872.70, with a market capitalisation of ₹1,801 Cr.
Windlas Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Domestic contract manufacturers).
Windlas Biotech Ltd has a P/E of 28 and a return on equity of 12.23%.
Windlas Biotech Ltd is listed on the NSE under the symbol WINDLAS and on the BSE under the scrip code 543329.
Windlas Biotech Ltd's share price is down 5.3% over one year and up 1.7% over three months. Its 52-week range is ₹697.40 to ₹1,181.90.
In Q1 FY27, Windlas Biotech Ltd reported revenue of ₹248 Cr and net profit of ₹18 Cr, with basic EPS of ₹8.46 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.